"These emissions drive global warming, exacerbating the very respiratory conditions inhalers are meant to relieve," ...

Nerandomilast is the first FDA-approved treatment for IPF in over a decade, targeting lung function decline. The FDA has ...

The U.S. Food and Drug Administration (FDA) approved sotatercept in March 2024 for treatment of pulmonary hypertension, ...

The use of anticoagulants is not associated with improved overall survival in patients with pulmonary arterial hypertension, ...

RAHWAY, N.J.- Merck has completed its $10 billion buyout of the British biopharmaceutical company Verona. The deal was first ...

A new treatment possibility for pulmonary fibrosis, which can cause serious breathing problems, but there is no proper ...

GoodRx reports over 5.6 million Americans live in "pulmonology deserts," lacking accessible lung care, mostly in the central ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the completion of the Verona Pharma plc ...

Inhalers are the frontline treatment for asthma and COPD, but they come with a steep environmental cost, according to a new ...

The University of the Sunshine Coast has begun trialling a three in one inhaler to target better lung and heart health outcomes in chronic obstructive ...

Inhalers are the frontline treatment for asthma and COPD, but they come with a steep environmental cost, according to a new UCLA Health study — the largest to date quantifying inhaler-related ...

Inhalers are the frontline treatment for asthma and COPD, but they come with a steep environmental cost, according to a new UCLA Health study - the largest to date quantifying inhaler-related ...